Ana Cláudia Frota Machado de Melo Lopes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ana Cláudia Frota Machado de Melo Lopes has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Bruno Cesar Correa Salles
Universidade Prof. Edson Antônio Vellano
2 shared publications - Gérsika Bitencourt Santos
Universidade Professor Edson Antônio Velano
2 shared publications - Roberta Bessa Veloso Silva
Universidade José do Rosário Vellano
2 shared publications - Sofia de Castro Oliveira
Universidade José do Rosário Vellano
2 shared publications - Aluísio Eustáquio de Freitas Miranda Filho
University of São Paulo, Brazil
1 shared publication - Cláudio Daniel Cerdeira
Universidade Federal de Alfenas
1 shared publication
Latest Publications
- Open Access
- 25 September 2026
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 48 (4) , 106535
The influence of Epstein-Barr virus in the microenvironment of classic Hodgkin lymphoma: A focus on T-cells and macrophages
- 25 September 2026
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 48 (4) , 106535
Open AccessThe influence of Epstein-Barr virus in the microenvironment of classic Hodgkin lymphoma: A focus on T-cells and macrophages
- Open Access
- 12 May 2026
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 28 (10) , 4738-4748
HER2 discordance between primary and metastatic gastric cancer: a systematic review and meta-analysis
Purpose: Gastric cancer (GC) remains a major global health burden, with poor survival rates. HER2 is a key biomarker for targeted therapy, but discordance between primary tumors and metastases may impact treatment decisions. This meta-analysis evaluated the prevalence and clinical relevance of HER2 status differences between primary gastric cancers and metastatic lesions. Methods: A systematic search of PubMed, Embase, and Cochrane was conducted for studies assessing HER2 status in matched primary and metastatic gastric cancer samples. Pooled proportions and 95% confidence intervals (CIs) were calculated using random-effects models. Subgroup analyses by metastatic site were performed. Statistical analyses were conducted using R software, version 4.2.3. Results: This meta-analysis included 3,515 patients across 20 studies. The pooled proportion of HER2-positive expression in primary gastric tumors was 13% (95% CI: 12–15%; I 2 = 68.7%), while HER2-negative tumors accounted for 74% (95% CI: 72%-76%; I 2 = 94.9%). In metastatic sites, the overall pooled proportion of HER2-positive lesions was 18% (95% CI: 16%-20%; I 2 = 77.3%), with notable variation across anatomical locations: 38% in lung metastases, 31% in liver metastases, 19% in lymph nodes, and 7% in peritoneum. Conversely, HER2-negative metastases accounted for 82% overall (95% CI: 80%-84%; I 2 = 78.2%), with proportions of 93% in peritoneum, 81% lymph nodes, 69% in liver metastases, and 62% in lung. Conclusions: Significant heterogeneity in HER2 expression between primary and metastatic gastric cancer underscores the need for reassessment of HER2 status in metastatic sites. Relying solely on primary tumor samples may lead to underestimation of HER2 positivity and suboptimal therapeutic decisions. Incorporating site-specific HER2 testing into clinical practice may enhance patient selection for HER2-targeted therapies and improve treatment outcomes. Graphic
- 12 May 2026
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 28 (10) , 4738-4748
Open AccessHER2 discordance between primary and metastatic gastric cancer: a systematic review and meta-analysis
Purpose: Gastric cancer (GC) remains a major global health burden, with poor survival rates. HER2 is a key biomarker for targeted therapy, but discordance between primary tumors and metastases may impact treatment decisions. This meta-analysis evaluated the prevalence and clinical relevance of HER2 status differences between primary gastric cancers and metastatic lesions. Methods: A systematic search of PubMed, Embase, and Cochrane was conducted for studies assessing HER2 status in matched primary and metastatic gastric cancer samples. Pooled proportions and 95% confidence intervals (CIs) were calculated using random-effects models. Subgroup analyses by metastatic site were performed. Statistical analyses were conducted using R software, version 4.2.3. Results: This meta-analysis included 3,515 patients across 20 studies. The pooled proportion of HER2-positive expression in primary gastric tumors was 13% (95% CI: 12–15%; I 2 = 68.7%), while HER2-negative tumors accounted for 74% (95% CI: 72%-76%; I 2 = 94.9%). In metastatic sites, the overall pooled proportion of HER2-positive lesions was 18% (95% CI: 16%-20%; I 2 = 77.3%), with notable variation across anatomical locations: 38% in lung metastases, 31% in liver metastases, 19% in lymph nodes, and 7% in peritoneum. Conversely, HER2-negative metastases accounted for 82% overall (95% CI: 80%-84%; I 2 = 78.2%), with proportions of 93% in peritoneum, 81% lymph nodes, 69% in liver metastases, and 62% in lung. Conclusions: Significant heterogeneity in HER2 expression between primary and metastatic gastric cancer underscores the need for reassessment of HER2 status in metastatic sites. Relying solely on primary tumor samples may lead to underestimation of HER2 positivity and suboptimal therapeutic decisions. Incorporating site-specific HER2 testing into clinical practice may enhance patient selection for HER2-targeted therapies and improve treatment outcomes. Graphic
- Open Access
- 2 October 2024
- Published by Fiocruz - Instituto de Tecnologia em Farmacos in Revista Fitos
- Vol. 18
Parâmetros bioquímicos e morfológicos em ratos diabéticos tratados com extratos de Ora-Pro-Nóbis (Pereskia aculeata)
Diabetes mellitus (DM) is a serious global public health problem. DM complications corroborate with high morbidity and mortality rates. Thus, several plant species have been studied regarding their medicinal properties with potential use in the treatment of DM and/or its complications. This study evaluated the effects of leaf (LE-OPN) and bark (BE-OPN) extracts from ora-pro-nóbis (Pereskia aculeata) on biochemical parameters (glycemia, triglycerides, total cholesterol, creatine, urea, AST and ALT, and lipid peroxidation) and histology (heart, liver and kidneys) in animals with DM. Induction of type 1 DM (glycemia > 200 mg/dl) in male Wistar rats was performed with Alloxane (150 mg/kg/ml). The animals were divided into 4 groups: (1) without DM, (2) with DM, (3) with DM treated with LE-OPN and (4) with DM treated with BE-OPN. The treatment was done by gavage (300 mg/kg/day) for 4 weeks. After this period the parameters were evaluated. BE-OPN prevented the increase in triglycerides, AST, ALT, and urea, in addition to lipid peroxidation (p < 0.05). The results suggest a potential for BE-OPN to prevent typical complications of DM, improving the lipid profile, liver, and kidney, as well as attenuating oxidative stress.
- 2 October 2024
- Published by Fiocruz - Instituto de Tecnologia em Farmacos in Revista Fitos
- Vol. 18
Open AccessParâmetros bioquímicos e morfológicos em ratos diabéticos tratados com extratos de Ora-Pro-Nóbis (Pereskia aculeata)
Diabetes mellitus (DM) is a serious global public health problem. DM complications corroborate with high morbidity and mortality rates. Thus, several plant species have been studied regarding their medicinal properties with potential use in the treatment of DM and/or its complications. This study evaluated the effects of leaf (LE-OPN) and bark (BE-OPN) extracts from ora-pro-nóbis (Pereskia aculeata) on biochemical parameters (glycemia, triglycerides, total cholesterol, creatine, urea, AST and ALT, and lipid peroxidation) and histology (heart, liver and kidneys) in animals with DM. Induction of type 1 DM (glycemia > 200 mg/dl) in male Wistar rats was performed with Alloxane (150 mg/kg/ml). The animals were divided into 4 groups: (1) without DM, (2) with DM, (3) with DM treated with LE-OPN and (4) with DM treated with BE-OPN. The treatment was done by gavage (300 mg/kg/day) for 4 weeks. After this period the parameters were evaluated. BE-OPN prevented the increase in triglycerides, AST, ALT, and urea, in addition to lipid peroxidation (p < 0.05). The results suggest a potential for BE-OPN to prevent typical complications of DM, improving the lipid profile, liver, and kidney, as well as attenuating oxidative stress.
- Open Access
- 1 May 2023
- Published by RECIMA21 - Revista Cientifica Multidisciplinar in RECIMA21 - Revista Científica Multidisciplinar
- Vol. 4 (5) , e453153
EFEITO DOS EXTRATOS DAS FOLHAS DE GUINÉ (PETIVERIA ALLIACEA L) SOBRE PARÂMETROS BIOQUÍMICOS E HISTOLÓGICOS EM RATOS DIABÉTICOS
O Diabetes Mellitus (DM) é um distúrbio endócrino e metabólico cada vez mais comum na população mundial, carente de novas alternativas terapêuticas, sendo os vegetais uma alternativa viável na busca por novos fitoterápicos e bioativos com ação para controlar o DM. Devido a atividade hipoglicemiante de alguns bioativos das folhas de Guiné (Petiveria alliacea), além de esta ser uma planta amplamente difundida pelo Brasil, de fácil cultivo e acesso, o presente estudo avaliou a influência dos extratos das folhas de Guiné sobre parâmetros bioquímicos e morfológicos de ratos Wistar com DM induzido por aloxano. Os animais foram divididos em três grupos experimentais: ratos sem DM (n = 10), ratos com DM (n = 10) e ratos com DM tratados com o extrato das folhas de P. alliacea (200mg/Kg/dia) (n = 10). Os parâmetros bioquímicos: glicose, perfil hepático (TGP e TGO), renal (creatinina e ureia) e lipídico (colesterol total e triglicerídeos), bem como a histologia de órgãos foram avaliadas. O extrato da folha de P. alliacea, na dose de 200mg/Kg/dia, não foi capaz de prevenir os aumentos dos níveis de glicose, TGP, TGO, creatinina, ureia, colesterol total e triglicerídeos, em animais com DM comparados ao grupo DM não tratado. Não houve alterações histopatológicas significativas no fígado, rins, coração, e glândulas salivares. Ressalta-se a necessidade de novos estudos para avaliar tais achados preliminares, visando esclarecer os efeitos aqui observados.
- 1 May 2023
- Published by RECIMA21 - Revista Cientifica Multidisciplinar in RECIMA21 - Revista Científica Multidisciplinar
- Vol. 4 (5) , e453153
Open AccessEFEITO DOS EXTRATOS DAS FOLHAS DE GUINÉ (PETIVERIA ALLIACEA L) SOBRE PARÂMETROS BIOQUÍMICOS E HISTOLÓGICOS EM RATOS DIABÉTICOS
O Diabetes Mellitus (DM) é um distúrbio endócrino e metabólico cada vez mais comum na população mundial, carente de novas alternativas terapêuticas, sendo os vegetais uma alternativa viável na busca por novos fitoterápicos e bioativos com ação para controlar o DM. Devido a atividade hipoglicemiante de alguns bioativos das folhas de Guiné (Petiveria alliacea), além de esta ser uma planta amplamente difundida pelo Brasil, de fácil cultivo e acesso, o presente estudo avaliou a influência dos extratos das folhas de Guiné sobre parâmetros bioquímicos e morfológicos de ratos Wistar com DM induzido por aloxano. Os animais foram divididos em três grupos experimentais: ratos sem DM (n = 10), ratos com DM (n = 10) e ratos com DM tratados com o extrato das folhas de P. alliacea (200mg/Kg/dia) (n = 10). Os parâmetros bioquímicos: glicose, perfil hepático (TGP e TGO), renal (creatinina e ureia) e lipídico (colesterol total e triglicerídeos), bem como a histologia de órgãos foram avaliadas. O extrato da folha de P. alliacea, na dose de 200mg/Kg/dia, não foi capaz de prevenir os aumentos dos níveis de glicose, TGP, TGO, creatinina, ureia, colesterol total e triglicerídeos, em animais com DM comparados ao grupo DM não tratado. Não houve alterações histopatológicas significativas no fígado, rins, coração, e glândulas salivares. Ressalta-se a necessidade de novos estudos para avaliar tais achados preliminares, visando esclarecer os efeitos aqui observados.